Document is current
Any future updates will be listed below
-
Authors
Xie, Junqing http://orcid.org/0000-0002-0040-0042
Feng, Yuliang
Newby, Danielle
Zheng, Bang
Feng, Qi
Prats-Uribe, Albert http://orcid.org/0000-0003-1202-9153
Li, Chunxiao
Wareham, Nicholas J. http://orcid.org/0000-0003-1422-2993
Paredes, R.
Prieto-Alhambra, Daniel http://orcid.org/0000-0002-3950-6346
- License Information
-
More Information
Article History
Received: 21 December 2022
Accepted: 19 July 2023
First Online: 3 August 2023
Competing interests
: DPA’s department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA’s department. Roger Paredes has participated in advisory boards for Gilead, MSD, ViiV Healthcare, Theratechnologies and Lilly. His institution has received research support from Gilead, MSD, and ViiV Healthcare. The remaining authors declare no competing interests.
